“Global Anxiety Disorders And Depression Treatment Market to reach a market value of USD 15.7 Billion by 2031 growing at a CAGR of 3.5%”
The Global Anxiety Disorders And Depression Treatment Market size is expected to reach $15.7 billion by 2031, rising at a market growth of 3.5% CAGR during the forecast period.
Anticonvulsants have been shown to help manage comorbid anxiety symptoms in patients with mood disorders. Their ability to address multiple aspects of a patient’s condition makes them a valuable treatment option. Lower Risk of Traditional Antidepressant Side Effects: Some anticonvulsants have a more favourable side effect profile compared to certain antidepressants, particularly concerning issues like sexual dysfunction or weight gain, making them a preferred choice for some patients. Thus, the Anticonvulsants segment attained 6% revenue share in the market in 2023.
The increasing emphasis on preventive care and early intervention has significantly impacted the anxiety disorders and depression treatment market. By identifying mental health issues at an earlier stage, healthcare providers can initiate treatment before the conditions become severe.
Additionally, the growing number of individuals experiencing these conditions has created a significant demand for effective treatments, including medications, psychotherapy, and other therapeutic interventions. As more people seek help for anxiety and depression, the market for treatments continues to expand.
However, the high cost of advanced treatments and therapies for anxiety disorders and depression can limit access to care for many individuals. Not everyone has sufficient financial resources or comprehensive insurance coverage to afford these treatments. As a result, people who need advanced therapies may forego treatment or opt for less effective alternatives, which can negatively impact their health outcomes.
On the basis of indication, the market is segmented into depression and anxiety. The anxiety segment recorded 55% revenue share in the market in 2023. Anxiety disorders are among the most common mental health conditions globally. Conditions such as generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder affect millions of people, driving significant demand for effective treatments.
Based on drugs, the market are divided into antidepressants, anxiolytics, anticonvulsants, noradrenergic agents, atypical antipsychotics. The atypical antipsychotics segment procured 24% revenue share in the market in 2023. Atypical antipsychotics can help manage both depressive and anxiety symptoms, as well as other symptoms like irritability and mood swings.
By distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. In 2023, the retail pharmacies segment registered 55% revenue share in the market. Retail pharmacies are widely accessible, making it easy for patients to obtain their medications without visiting specialized clinics or hospitals.
Free Valuable Insights: Global Anxiety Disorders And Depression Treatment Market size to reach USD 15.7 Billion by 2031
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2023, the Asia Pacific region generated 26% revenue share in the market. There has been a growing awareness and recognition of mental health issues across the Asia-Pacific region.
| Report Attribute | Details |
|---|---|
| Market size value in 2023 | USD 12.1 Billion |
| Market size forecast in 2031 | USD 15.7 Billion |
| Base Year | 2023 |
| Historical Period | 2020 to 2022 |
| Forecast Period | 2024 to 2031 |
| Revenue Growth Rate | CAGR of 3.5% from 2024 to 2031 |
| Number of Pages | 259 |
| Number of Tables | 360 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Indication, Drugs, Distribution Channel, Region |
| Country scope |
|
| Companies Included | Pfizer Inc., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Eli Lilly And Company, AstraZeneca PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Sanofi S.A, Takeda Pharmaceutical Company Limited |
By Indication
By Drugs
By Distribution Channel
By Geography
The Market size is projected to reach USD 15.7 billion by 2031.
Rising investment in mental health research are driving the Market in coming years, however, High cost of advanced treatments and therapies restraints the growth of the Market.
Pfizer Inc., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Eli Lilly And Company, AstraZeneca PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Sanofi S.A, Takeda Pharmaceutical Company Limited
The expected CAGR of this Market is 3.5% from 2024 to 2031.
The Antidepressants segment is leading the Market by Drugs in 2023; thereby, achieving a market value of $4.8 billion by 2031.
The North America region dominated the Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $5.6 billion by 2031.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 